COCONUT CREEK, Fla., June 22, 2021 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTC: PSYBF) (“ PsyBio” or the “Company“), an intellectual property driven biotechnology company researching and developing novel formulations of psychoactive medications produced by genetically modified bacteria for the potential treatment of mental health challenges and other disorders, has initiated its first…


Previous articleInterview: Dr. Josh Woolley (TrPR) and Ben Lightburn (Filament Health)
Next articleFilament Health Corp. Announces Approval for Listing on the Neo Exchange